Search results
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 18 hours agoAbstract #9507: Analysts have closely tracked a dual-targeting antibody drug that Immunocore is developing for a type of skin cancer called cutaneous...
Biogen enters deal to acquire HI-Bio for $1.8bn
Pharmaceutical Technology via Yahoo Finance· 23 hours agoHI-Bio specialises in targeted treatments for severe immune-mediated diseases (IMDs). Its lead asset, felzartamab, is a fully human anti-CD38 monoclonal ...
The FLiRT COVID variants: What are they and are they more contagious?
Reuters· 2 hours agoThe moniker FLiRT is an acronym for the locations of the mutations the variants share on the virus'...
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows
InvestorPlace· 2 hours agoGlobal stocks are surging. The MSCI ACWI Index, which encompasses both developed and emerging...
Breaking down barriers: NC’s grassroots groups bridge the gap in fight against HIV
Raleigh News and Observer via Yahoo News· 3 days agoRaymond Velazquez stood in the Asheville post office in a daze. Holding a letter from the blood bank...
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a...
Benzinga· 4 hours agoSHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed
ASCO 2024: Advancements in Metastatic Breast Cancer
Medscape· 1 day agoDr Kevin M. Kalinsky previews updates on antibody-drug conjugates, combination therapies, and targeted treatments in metastatic breast cancer.
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 15 hours agoRagistomig was designed as a bispecific antibody to provide anti-PD-L1 activity and 4-1BB-driven T-cell activation in one molecule.
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoOn May 22, 2024, NeoMab Biotechnology (Suzhou) Co., Ltd. celebrated its grand opening in Suzhou Industrial Park (BioBAY). This marks a significant milestone that will further enhance the high-quality ...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...
Morningstar· 2 days agoHI-Bio’s lead asset, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to selectively deplete CD38+ cells including plasma ...
